Amarin (AMRN) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Amarin (AMRN) over the past year, gaining 4.1% versus a loss of 37.8%. Over five years, IFRX leads with a -38.1% price change compared with -88.4% for AMRN. Amarin is the larger company by market cap ($254.1 million vs $238.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | IFRX |
|---|---|---|
| Share price | $12.03 | $1.62 |
| Market cap | $254.11M | $238.74M |
| 1-day change | +0.33% | +5.90% |
| YTD return | -14.11% | +51.49% |
| 1-year return | -37.81% | +4.08% |
| 5-year return | -88.38% | -38.06% |
| Forward P/E | 12.28 | — |
| EPS (TTM) | $-1.20 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $2.95 |
| 52-week low | $11.83 | $0.798 |
| Distance from 52-week high | -42.44% | -45.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +3.91% | +374.07% |
| Average volume | 66.23K | 798.72K |
| Shares outstanding | 21.12M | 147.37M |
| Employees | 80 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed AMRN by 41.9 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
AMRN vs IFRX FAQ
Which is bigger, Amarin or InflaRx N.V.?
Amarin (AMRN) is larger, with a market capitalization of $254.11M compared with $238.74M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, AMRN or IFRX?
IFRX returned +4.08% over the past 12 months, compared with -37.81% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.